EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
    1.3.98.1 | Autoimmune Diseases |
20310011 |
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 1.3.98.1 | Leukemia, Myeloid |
34353411 |
A combined Chemical, Computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in Acute Myeloid Leukemia cells. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
3
3
4
0 |
| 1.3.98.1 | Leukemia, Myeloid, Acute |
34353411 |
A combined Chemical, Computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in Acute Myeloid Leukemia cells. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
3
3
4
0 |
| 1.3.98.1 | COVID-19 |
33406218 |
A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 1.3.98.1 | Neoplasms |
29549331 |
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. |
causal interaction
unassigned |
2
0 |
| 1.3.98.1 | Malaria |
27133204 |
A high-throughput fluorescence-based assay for Plasmodium dihydroorotate dehydrogenase inhibitor screening. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 1.3.98.1 | Malaria |
26180101 |
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. |
causal interaction
therapeutic application
unassigned |
1
4
0 |
| 1.3.98.1 | Autoimmune Diseases |
32696396 |
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
1
3
4 |
| 1.3.98.1 | COVID-19 |
32696396 |
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
1
3
4 |
| 1.3.98.1 | Foot-and-Mouth Disease |
31545264 |
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. |
therapeutic application
unassigned |
4
0 |
